BACKGROUND: Standardized, evidence-based guidelines recommend lung resection for patients with stage I or II nonsmall-cell lung cancer (NSCLC), and select patients with stage IIIA disease. We hypothesized that the proportion of patients operated on would increase over time coincident with increasing adherence to practice guidelines and improved patient/provider education over time. METHODS: This investigation was a cohort study of tumor-registry data linked to Medicare claims. RESULTS: Between 1992 and 2002, 24,030 patients--mean age 75 +/- 6 years, 55% men--were diagnosed with NSCLC. In each stage, the proportion of patients undergoing resection was lower in 2002 compared with 1992: stage I (68% versus 80%, p < 0.001), II (59% versus 74%, p < 0.001), and IIIA (23% versus 35%, p < 0.001). The mean age and comorbidity index of the cohort was higher in 2002 compared with 1992 (76 versus 74 years, p < 0.001; and 0.47 and 0.82, p < 0.001, respectively). The unadjusted odds of resection decreased by 6% per year (odds ratio 0.94, 99% confidence interval: 0.93 to 0.95), and adjustment for age, comorbidity index, race, and stage resulted in a slightly smaller (4% per year) but significantly decreasing trend in operative management over time (odds ratio 0.96, 99% confidence interval: 0.95 to 0.97). CONCLUSIONS: Unexpectedly, the use of resection for lung cancer has decreased dramatically over time, and this decline is not fully accounted for by an older cohort with more comorbid conditions. Future investigations should determine whether increasing unmeasured contraindications to resection, barriers to accessing specialty care, an inadequate supply of thoracic surgeons, or bias against operative therapy are responsible.
BACKGROUND: Standardized, evidence-based guidelines recommend lung resection for patients with stage I or II nonsmall-cell lung cancer (NSCLC), and select patients with stage IIIA disease. We hypothesized that the proportion of patients operated on would increase over time coincident with increasing adherence to practice guidelines and improved patient/provider education over time. METHODS: This investigation was a cohort study of tumor-registry data linked to Medicare claims. RESULTS: Between 1992 and 2002, 24,030 patients--mean age 75 +/- 6 years, 55% men--were diagnosed with NSCLC. In each stage, the proportion of patients undergoing resection was lower in 2002 compared with 1992: stage I (68% versus 80%, p < 0.001), II (59% versus 74%, p < 0.001), and IIIA (23% versus 35%, p < 0.001). The mean age and comorbidity index of the cohort was higher in 2002 compared with 1992 (76 versus 74 years, p < 0.001; and 0.47 and 0.82, p < 0.001, respectively). The unadjusted odds of resection decreased by 6% per year (odds ratio 0.94, 99% confidence interval: 0.93 to 0.95), and adjustment for age, comorbidity index, race, and stage resulted in a slightly smaller (4% per year) but significantly decreasing trend in operative management over time (odds ratio 0.96, 99% confidence interval: 0.95 to 0.97). CONCLUSIONS: Unexpectedly, the use of resection for lung cancer has decreased dramatically over time, and this decline is not fully accounted for by an older cohort with more comorbid conditions. Future investigations should determine whether increasing unmeasured contraindications to resection, barriers to accessing specialty care, an inadequate supply of thoracic surgeons, or bias against operative therapy are responsible.
Authors: Jennifer L Lund; Til Stürmer; Linda C Harlan; Hanna K Sanoff; Robert S Sandler; Maurice Alan Brookhart; Joan L Warren Journal: Med Care Date: 2013-05 Impact factor: 2.983
Authors: Frank C Detterbeck; Justin D Blasberg; Gavitt A Woodard; Roy H Decker; Ulas Kumbasar; Henry S Park; Vincent J Mase; Brett C Bade; Andrew X Li; Whitney S Brandt; David C Madoff Journal: J Thorac Dis Date: 2022-06 Impact factor: 3.005
Authors: Angela C Tramontano; Lauren E Cipriano; Chung Yin Kong; Jo-Anne O Shepard; Michael Lanuti; G Scott Gazelle; Pamela M McMahon Journal: AJR Am J Roentgenol Date: 2013-05 Impact factor: 3.959
Authors: Mark F Berry; Brooke K Coleman; Lesley H Curtis; Mathias Worni; Thomas A D'Amico; Igor Akushevich Journal: Ann Surg Oncol Date: 2014-09-06 Impact factor: 5.344
Authors: Ben C Creelan; Scott Antonia; Gerold Bepler; Timothy J Garrett; George R Simon; Hatem H Soliman Journal: Oncoimmunology Date: 2013-03-01 Impact factor: 8.110
Authors: Chandylen L Nightingale; Laurie E Steffen; Janet A Tooze; William Petty; Suzanne C Danhauer; Hoda Badr; Kathryn E Weaver Journal: Glob Adv Health Med Date: 2019-07-17
Authors: Ian C Bostock; Wayne Hofstetter; Reza Mehran; Ravi Rajaram; David Rice; Boris Sepesi; Stephen Swisher; Ara Vaporciyan; Garrett Walsh; Mara B Antonoff Journal: J Thorac Dis Date: 2021-12 Impact factor: 2.895